Abnormal expression or mutations of EIF4A3 have been associated with various types of cancer, suggesting that the increased m6A levels observed in many cancers may be a result of aberrant splicing machinery and incomplete protection of exon junctions by the EJC. This evidence concerns the gene EIF4A3 and cancer.